查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1224492

细胞和基因治疗製造市场规模、份额和趋势分析:按治疗类型、规模(研发)、模式、流程(载体生产、细胞库)、地区、市场,2023-2030

Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report By Therapy Type, By Scale (R&D), By Mode, By Workflow (Vector Production, Cell Banking), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 217 Pages | 商品交期: 2-10个工作天内

价格

细胞和基因治疗製造的市场增长和趋势

根据 Grandview Research 的一份新报告，到 2030 年，全球细胞和基因疗法製造市场预计将达到 471 亿美元。 2023 年至 2030 年，该市场的复合年增长率预计为 26.6%，这是由于临床管道的快速进展和先进疗法的监管批准数量增加，这是市场增长的主要促进因素。

政府当局和主要市场参与者的大量投资也在推动细胞和基因疗法製造业的增长。 在过去十年中，公司在基因治疗方面的投资约为 23 亿美元。 包括 CDMO/CMO 和内部製造商在内的主要服务提供商将这些疗法视为活跃的投资领域。 例如，2020 年 5 月，Thermo Fisher Scientific 还投资 1.8 亿美元，将其病毒载体製造能力提高一倍。 这些参与者正在通过大力投资建设和/或扩大製造能力或与竞争对手建立战略联盟来增加他们的市场占有率。 因此，这些因素有望成为该市场的主要促进因素。

进入临床试验并获得监管机构上市许可的细胞和基因治疗药物的数量每年都在增加。 截至2019年底，已有17个细胞和基因治疗产品获得美国FDA批准上市。 美国 FDA 预计从 2020 年初开始，每年将收到 200 多个基因和细胞治疗 IND。 该监管机构还计划从 2025 年起每年批准多达 20 种产品。 预计政府的这种支持性努力将在不久的将来推动对细胞和基因治疗製造服务的需求。

根据 2020 年 3 月发表的一篇文章，2019 年初美国处于管线（III 期试验）的细胞和基因治疗药物数量为 289 种，但 2020 年初步达到 362 种。 考虑到临床前管道，这个数字预计会翻倍。 这一数字的增长表明对细胞和基因治疗製造服务的强劲需求。 根据美国生物製药公司的一份报告，基因和细胞疗法正处于早期到晚期的临床开发阶段，重点是治疗多种疾病，包括神经系统疾病、遗传疾病和癌症。

细胞和基因疗法製造市场报告要点

细胞疗法製造业在 2022 年的收入方面占据了市场主导地位。 越来越多的正在进行的临床试验和越来越多的研究导致了该领域的主导地位

2022 年，处于商业化规模前阶段的大量候选分子贡献了商业化前规模製造细分市场的最大收入份额

随着对基因和细胞治疗产品的监管批准越来越多，对这些疗法的商业化生产的需求正在迅速增长，从而增加了商业规模製造领域的份额。

由于许多生物製造商利用 CMO 进行高效快速的产品开发，预计合同製造行业在预测期内将实现利润丰厚的增长。

此外，临床管线的持续增加也被认为是加速合同製造行业增长的因素之一。

由于基因治疗相关研发的进步以及地区政府增加的投资，北美在收入方面占据了全球市场的主导地位。

预计亚太地区在预测期内将以最快的速度增长。

这是由更快的审批速度、增加的私人和政府投资以及不断增长的医疗保健需求推动的。

目次

第 1 章调查方法及范围

  • 调查方法
  • 调查假设
  • 调查方法
  • 资讯采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要资讯
    • 初步调查
    • 初步调查的详细资讯
  • 资讯或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细资讯
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐个国家/地区进行市场估算
  • 市场：CAGR 计算
  • 二级资讯列表
  • 目的

第 2 章执行摘要

  • 竞争环境
  • 细分市场展望
  • 2022 年市场概览（百万美元）

第 3 章市场变量、趋势和范围

  • 市场细分
  • 母市场血统
  • 辅助市场系统
  • 治疗类型渗透率和增长前景图，2022 年
  • 市场动态
    • 市场促进因素分析
      • 培养细胞和基因治疗管线
      • 合作监管机构
      • 政府和私营公司的投资增加
    • 市场抑制因素分析
      • 与製造相关的技术问题
      • 製造成本高
    • 市场机会分析
      • 药物开发商/製造商在满足不断增长的市场需求方面面临的压力越来越大
      • 拓展亚太地区和拉丁美洲等潜在市场
    • 市场问题分析
      • 製造能力不足
  • SWOT 分析；按因素（政治和法律、经济、技术）
  • 波特的五力分析
  • 对主要交易和战略联盟的分析
    • 併购
    • 技术合作
    • 许可和合作伙伴关係
  • COVID-19 影响分析
    • 问题分析
    • 机会分析
    • 主要发展和活动

第 4 章关注製造商

  • 製造细胞和基因疗法
    • 扩大细胞和基因治疗设施
    • 对主要交易和战略联盟的分析
    • 併购
    • 技术合作与伙伴关係
    • 产品批准和发布
  • 细胞和基因治疗药物製造的成本分析
    • 产品分析的总成本
    • 原材料
    • 劳动力成本
    • 过程成本
    • 成本模型
    • 广告模型
    • 日常模型
    • 混合模型
    • 按技术进行商品成本分析
    • 材料
    • 设备
    • 人力资源
    • 设施

第 5 章处理类型的业务分析

  • 细胞和基因疗法的製造市场：治疗类型的变化分析
  • 製造细胞疗法
    • 干细胞疗法
    • 非干细胞疗法
  • 基因疗法製造

第 6 章製造规模业务分析

  • 细胞和基因疗法製造市场：规模波动分析
  • 预商业/研发规模製造
  • 商业规模製造

第 7 章模式业务分析

  • 细胞和基因疗法的製造市场：模态变化分析
  • 合同製造
    • 合同製造细胞和基因治疗製造市场，2018-2030 年（百万美元）（数量、剂量）
  • 内部製造
    • 内部细胞和基因疗法的製造市场，2018-2030 年（百万美元）（数量、剂量）

第 8 章工作流业务分析

  • 细胞和基因疗法的製造市场：工作流程变化分析
  • 细胞处理
  • 细胞银行
  • 流程开发
  • 填充并完成操作
  • 分析和质量测试
  • 原材料测试
  • 载体生产
  • 其他

第 9 章区域业务分析

  • 北美
    • SWOT 分析
    • 美国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 加拿大
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 欧洲
    • SWOT 分析
    • 德国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 英国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 法国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 义大利
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 西班牙
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 丹麦
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 瑞典
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 挪威
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 亚太地区
    • SWOT 分析
      • 主要区域动态
    • 日本
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 中国
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 印度
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 韩国
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 澳大利亚
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 泰国
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 拉丁美洲
    • SWOT 分析：
    • 主要地区动态
    • 巴西
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 墨西哥
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 阿根廷
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 中东和非洲 (MEA)
    • SWOT 分析
    • 主要地区动态
    • 南非
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 沙特阿拉伯
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 阿拉伯联合酋长国
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 科威特
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景

第 10 章竞争格局

  • 战略框架
  • 市场准入分类
  • 公司简介
    • Thermo Fisher Scientific, Inc.
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
    • Merck Kgaa
      • 公司概况
      • Milliporesigma
      • 财务业绩
      • 产品基准
      • 战略举措
    • Lonza
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Catalent, Inc.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Takara Bio, Inc.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • F. Hoffmann-La Roche Ltd.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Wuxi Advanced Therapies
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Samsung
      • 公司简介
      • Samsung Biologics
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Boehringer Ingelheim International Gmbh
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Novartis Ag
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • Hitachi Chemical Co., Ltd.（Showa Denko Materials Co Ltd）
      • 公司概况
      • Apceth Biopharma
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
    • Cellular Therapeutics
      • 公司概况
      • 产品基准
    • Miltenyi Biotech
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
    • Bluebird Bio Inc.
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
  • 按主要公司分类：近期发展和影响分析
  • 企业地图
  • 供应商情况
    • 主要分销商和渠道合作伙伴列表
    • 2022 年主要参与者的市场份额分析
  • 上市公司
    • 公司市场分析
    • 竞争仪表板分析
  • 私人公司
    • 主要初创企业名单
    • 本地网路地图
    • 公司市场分析
Product Code: GVR-4-68038-289-1

Cell And Gene Therapy Manufacturing Market Growth & Trends:

The global cell and gene therapy manufacturing market size is expected to reach USD 47.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 26.6% from 2023 to 2030 owing to the exponential progress of the clinical pipeline, coupled with a rising number of regulatory approvals for advanced therapies, which has majorly driven the growth of the market.

Significant investments by government authorities and key market players are other factors fueling the growth of cell and gene therapy manufacturing. Around USD 2.3 billion was invested in gene therapies by companies over the last decade. Major service providers, including CDMOs/CMOs and in-house manufacturers, consider these therapies as an active area of investment. For instance, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. These players are investing significant amounts either in building and/or expanding manufacturing capabilities or forming strategic alliances with competitors to boost their market presence. Thus, these factors are anticipated to act as primary driving factors for this market.

The number of cell and gene therapies entering clinical trials and later gaining marketing authorization from regulatory bodies is increasing every year. By the end of 2019, 17 cell and gene therapy products were approved by the U.S. FDA for commercial use. The U.S. FDA is expecting to receive over 200 gene and cell treatment INDs annually from the beginning of 2020. The regulatory body is also planning to approve up to 20 products per year from 2025. Such supportive government initiatives are expected to increase the demand for cell and gene therapy manufacturing services in the near future.

Following an article published in March 2020, in the U.S., the number of cell and gene therapies in the pipeline (phase III trials) was 289 at the beginning of 2019, which reached 362 in early 2020. The number is expected to increase twofold if the preclinical pipeline is considered. This growing number indicates the high demand for manufacturing services for cell and gene therapies. According to a report by America's Biopharmaceutical Companies, gene and cell therapies range from early to late stages of clinical development with a focus on a wide spectrum of diseases, including neurologic conditions, genetic disorders, and cancer.

Cell And Gene Therapy Manufacturing Market Report Highlights:

  • The cell therapy manufacturing segment dominated the 2022 market in terms of revenue. A growing number of ongoing clinical trials and increasing research in this space has resulted in the segment dominance
  • A high number of candidate molecules in the pre-commercial scale stage has contributed to the largest revenue share for the pre-commercial scale manufacturing market segment in 2022
  • With an increasing number of regulatory approvals for gene and cell therapy products, the demand for commercial production of these therapies is increasing rapidly, thereby increasing the share of the commercial-scale manufacturing segment
  • The contract manufacturing segment is expected to witness lucrative growth during the forecast period, as a substantial number of biomanufacturers are turning to CMOs for efficient and rapid product development
  • Moreover, the constantly growing clinical pipeline is another contributing factor expected to accelerate contract manufacturing segment growth
  • North America dominated the global market in terms of revenue owing to advancements in research and development pertaining to gene therapy and the increasing number of investments by the regional governments
  • The Asia Pacific region is anticipated to grow at the fastest rate throughout the forecast period
  • This can be attributed to the establishment of accelerated approval pathways, growing private and government investments, and increasing healthcare needs

Table of Content

Chapter 1 Methodology And Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 Gvr's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
    • 1.4.5 Details Of Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity Flow Approach
      • 1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.8 Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2

Chapter 2 Executive Summary

  • 2.1 Competition Milieu
  • 2.2 Segment Outlook
  • 2.3 Market Summary, 2022 (USD Million)

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Market Segmentation
  • 3.2 Parent Market Lineage
  • 3.3 Ancillary Market Lineage
  • 3.4 Penetration and Growth Prospect Mapping for Therapy Type, 2022
  • 3.5 Market Dynamics
    • 3.5.1 Market Drivers Analysis
      • 3.5.1.1 Growing Pipeline Of Cell And Gene Therapy
      • 3.5.1.2 Supportive Regulatory Bodies
      • 3.5.1.3 Increase In Investment By Government And Private Players
    • 3.5.2 Market Restraint Analysis
      • 3.5.2.1 Technological Challenges Associated With Manufacturing
      • 3.5.2.2 High Cost Of Manufacturing
    • 3.5.3 Market Opportunity Analysis
      • 3.5.3.1 Rising Pressure On Drug Developers/Manufacturers To Meet The Growing Market Demand
      • 3.5.3.2 Expansion In Potential Markets Such As Asia Pacific And Latin America
    • 3.5.4 Market Challenge Analysis
      • 3.5.4.1 Lack Of Manufacturing Capacity
  • 3.6 Swot Analysis; By Factor (Political & Legal, Economic, And Technological)
  • 3.7 Porter's Five Forces Analysis
  • 3.8 Major Deals And Strategic Alliances Analysis
    • 3.8.1 Mergers And Acquisitions
    • 3.8.2 Technological Collaborations
    • 3.8.3 Licensing And Partnerships
  • 3.9 Covid-19 Impact Analysis
    • 3.9.1 Challenge Analysis
    • 3.9.2 Opportunity Analysis
    • 3.9.3 Key Developments And Activities

Chapter 4 Focus On Manufacturers

  • 4.1 Cell And Gene Therapy Manufacturing
    • 4.1.1 Facility Expansion For Cell And Gene Therapies
    • 4.1.2 Major Deals And Strategic Alliances Analysis
    • 4.1.3 Mergers And Acquisitions
    • 4.1.4 Technological Collaborations And Partnerships
    • 4.1.5 Product Approvals And Launch
  • 4.2 Cost Of Goods Analysis In Cell And Gene Therapy Manufacturing
    • 4.2.1 Overall Cost Of Goods Analysis
    • 4.2.2 Raw Material
    • 4.2.3 Labor Costs
    • 4.2.4 Process Costs
    • 4.2.5 Cost Models
    • 4.2.6 Campaign Model
    • 4.2.7 Day Rate Model
    • 4.2.8 Hybrid Model
    • 4.2.9 Cost Of Goods Analysis, By Technique
    • 4.2.10 Materials
    • 4.2.11 Equipment
    • 4.2.12 Personnel
    • 4.2.13 Facility

Chapter 5 Therapy Type Business Analysis

  • 5.1 Cell and Gene Therapy Manufacturing Market: Therapy Type Movement Analysis
  • 5.2 Cell Therapy Manufacturing
    • 5.2.1 Cell Therapy Manufacturing Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
    • 5.2.2 Stem Cell Therapy
    • 5.2.3 Cell Therapy Manufacturing Market Estimates And Forecast For Stem Cell Therapy, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
    • 5.2.4 Non-Stem Cell Therapy
    • 5.2.5 Cell Therapy Manufacturing Market Estimates And Forecast For Non-Stem Cell Therapy, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
  • 5.3 Gene Therapy Manufacturing
    • 5.3.1 Gene Therapy Manufacturing Market Estimates And Forecast, 2018 - 2030 (USD Million) (Volume, Number Of Doses)

Chapter 6 Manufacturing Scale Business Analysis

  • 6.1 Cell And Gene Therapy Manufacturing Market: Scale Movement Analysis
  • 6.2 Precommercial/R&D Scale Manufacturing
    • 6.2.1 Cell And Gene Therapy Manufacturing Market Estimates And Forecast For Precommercial/R&D Scale Manufacturing, 2018 - 2030 (USD Million)
  • 6.3 Commercial-Scale Manufacturing
    • 6.3.1 Cell And Gene Therapy Manufacturing Market Estimates And Forecast For Commercial-Scale Manufacturing, 2018 - 2030 (USD Million)

Chapter 7 Mode Business Analysis

  • 7.1 Cell And Gene Therapy Manufacturing Market: Mode Movement Analysis
  • 7.2 Contract Manufacturing
    • 7.2.1 Cell And Gene Therapy Manufacturing Market For Contract Manufacturing, 2018 - 2030 (USD Million) (Volume, Number Of Doses)
  • 7.3 In-House Manufacturing
    • 7.3.1 Cell And Gene Therapy Manufacturing Market For In-House Manufacturing, 2018 - 2030 (USD Million) (Volume, Number Of Doses)

Chapter 8 Workflow Business Analysis

  • 8.1 Cell And Gene Therapy Manufacturing Market: Workflow Movement Analysis
  • 8.2 Cell Processing
    • 8.2.1 Cell And Gene Therapy Manufacturing Market For Cell Processing, 2018 - 2030 (USD Million)
  • 8.3 Cell Banking
    • 8.3.1 Cell And Gene Therapy Manufacturing Market For Cell Banking, 2018 - 2030 (USD Million)
  • 8.4 Process Development
    • 8.4.1 Cell And Gene Therapy Manufacturing Market For Process Development, 2018 - 2030 (USD Million)
  • 8.5 Fill And Finish Operations
    • 8.5.1 Cell And Gene Therapy Manufacturing Market For Fill And Finish Operations, 2018 - 2030 (USD Million)
  • 8.6 Analytical And Quality Testing
    • 8.6.1 Cell And Gene Therapy Manufacturing Market For Analytical And Quality Testing, 2018 - 2030 (USD Million)
  • 8.7 Raw Material Testing
    • 8.7.1 Cell And Gene Therapy Manufacturing Market For Raw Material Testing, 2018 - 2030 (USD Million)
  • 8.8 Vector Production
    • 8.8.1 Cell And Gene Therapy Manufacturing Market For Vector Production, 2018 - 2030 (USD Million)
  • 8.9 Others
    • 8.9.1 Cell And Gene Therapy Manufacturing Market For Others, 2018 - 2030 (USD Million)

Chapter 9 Regional Business Analysis

  • 9.1 North America
    • 9.1.1 Swot Analysis
      • 9.1.1.1 North America Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.1.2 U.S.
      • 9.1.2.1 Key Country Dynamics
      • 9.1.2.2 Target Disease Prevalence
      • 9.1.2.3 Competitive Scenario
      • 9.1.2.4 Regulatory Framework
      • 9.1.2.5 Reimbursement Scenario
      • 9.1.2.6 U.S. Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.1.3 Canada
      • 9.1.3.1 Key Country Dynamics
      • 9.1.3.2 Target Disease Prevalence
      • 9.1.3.3 Competitive Scenario
      • 9.1.3.4 Regulatory Framework
      • 9.1.3.5 Reimbursement Scenario
      • 9.1.3.6 Canada Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2 Europe
    • 9.2.1 Swot Analysis
      • 9.2.1.1 Europe Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2 Germany
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 Target Disease Prevalence
      • 9.2.2.3 Competitive Scenario
      • 9.2.2.4 Regulatory Framework
      • 9.2.2.5 Reimbursement Scenario
      • 9.2.2.6 Germany Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3 U.K.
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Target Disease Prevalence
      • 9.2.3.3 Competitive Scenario
      • 9.2.3.4 Regulatory Framework
      • 9.2.3.5 Reimbursement Scenario
      • 9.2.3.6 UK Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.4 France
      • 9.2.4.1 Key Country Dynamics
      • 9.2.4.2 Target Disease Prevalence
      • 9.2.4.3 Competitive Scenario
      • 9.2.4.4 Regulatory Framework
      • 9.2.4.5 Reimbursement Scenario
      • 9.2.4.6 France Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.5 Italy
      • 9.2.5.1 Key Country Dynamics
      • 9.2.5.2 Target Disease Prevalence
      • 9.2.5.3 Competitive Scenario
      • 9.2.5.4 Regulatory Framework
      • 9.2.5.5 Reimbursement Scenario
      • 9.2.5.6 Italy Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.6 Spain
      • 9.2.6.1 Key Country Dynamics
      • 9.2.6.2 Target Disease Prevalence
      • 9.2.6.3 Competitive Scenario
      • 9.2.6.4 Regulatory Framework
      • 9.2.6.5 Reimbursement Scenario
      • 9.2.6.6 Spain Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.2.7 Denmark
      • 9.2.7.1 Key Country Dynamics
      • 9.2.7.2 Target Disease Prevalence
      • 9.2.7.3 Competitive Scenario
      • 9.2.7.4 Regulatory Framework
      • 9.2.7.5 Reimbursement Scenario
      • 9.2.7.6 Denmark Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.8 Sweden
      • 9.2.8.1 Key Country Dynamics
      • 9.2.8.2 Target Disease Prevalence
      • 9.2.8.3 Competitive Scenario
      • 9.2.8.4 Regulatory Framework
      • 9.2.8.5 Reimbursement Scenario
      • 9.2.8.6 Sweden Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.9 Norway
      • 9.2.9.1 Key Country Dynamics
      • 9.2.9.2 Target Disease Prevalence
      • 9.2.9.3 Competitive Scenario
      • 9.2.9.4 Regulatory Framework
      • 9.2.9.5 Reimbursement Scenario
      • 9.2.9.6 Norway Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3 Asia Pacific
    • 9.3.1 SWOT Analysis
      • 9.3.1.1 Key Region Dynamics
      • 9.3.1.2 Asia Pacific Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 Japan
      • 9.3.2.1 Target Disease Prevalence
      • 9.3.2.2 Competitive Scenario
      • 9.3.2.3 Regulatory Framework
      • 9.3.2.4 Reimbursement Scenario
      • 9.3.2.5 Japan Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3 China
      • 9.3.3.1 Target Disease Prevalence
      • 9.3.3.2 Competitive Scenario
      • 9.3.3.3 Regulatory Framework
      • 9.3.3.4 Reimbursement Scenario
      • 9.3.3.5 China Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4 India
      • 9.3.4.1 Target Disease Prevalence
      • 9.3.4.2 Competitive Scenario
      • 9.3.4.3 Regulatory Framework
      • 9.3.4.4 Reimbursement Scenario
      • 9.3.4.5 India Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5 South Korea
      • 9.3.5.1 Target Disease Prevalence
      • 9.3.5.2 Competitive Scenario
      • 9.3.5.3 Regulatory Framework
      • 9.3.5.4 Reimbursement Scenario
      • 9.3.5.5 South Korea Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6 Australia
      • 9.3.6.1 Target Disease Prevalence
      • 9.3.6.2 Competitive Scenario
      • 9.3.6.3 Regulatory Framework
      • 9.3.6.4 Reimbursement Scenario
      • 9.3.6.5 Australia Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7 Thailand
      • 9.3.7.1 Target Disease Prevalence
      • 9.3.7.2 Competitive Scenario
      • 9.3.7.3 Regulatory Framework
      • 9.3.7.4 Reimbursement Scenario
      • 9.3.7.5 Thailand Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4 Latin America
    • 9.4.1 Swot Analysis:
    • 9.4.2 Key Regional Dynamics
      • 9.4.2.1 Latin America Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3 Brazil
      • 9.4.3.1 Target Disease Prevalence
      • 9.4.3.2 Competitive Scenario
      • 9.4.3.3 Regulatory Framework
      • 9.4.3.4 Reimbursement Scenario
      • 9.4.3.5 Brazil Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4 Mexico
      • 9.4.4.1 Target Disease Prevalence
      • 9.4.4.2 Competitive Scenario
      • 9.4.4.3 Regulatory Framework
      • 9.4.4.4 Reimbursement Scenario
      • 9.4.4.5 Mexico Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5 Argentina
      • 9.4.5.1 Target Disease Prevalence
      • 9.4.5.2 Competitive Scenario
      • 9.4.5.3 Regulatory Framework
      • 9.4.5.4 Reimbursement Scenario
      • 9.4.5.5 Argentina Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5 Middle East & Africa (MEA)
    • 9.5.1 Swot Analysis
    • 9.5.2 Key Regional Dynamics
      • 9.5.2.1 Middle East & Africa Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3 South Africa
      • 9.5.3.1 Target Disease Prevalence
      • 9.5.3.2 Competitive Scenario
      • 9.5.3.3 Regulatory Framework
      • 9.5.3.4 Reimbursement Scenario
      • 9.5.3.5 South Africa Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.4 Saudi Arabia
      • 9.5.4.1 Target Disease Prevalence
      • 9.5.4.2 Competitive Scenario
      • 9.5.4.3 Regulatory Framework
      • 9.5.4.4 Reimbursement Scenario
      • 9.5.4.5 Saudi Arabia Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.5 UAE
      • 9.5.5.1 Target Disease Prevalence
      • 9.5.5.2 Competitive Scenario
      • 9.5.5.3 Regulatory Framework
      • 9.5.5.4 Reimbursement Scenario
      • 9.5.5.5 UAE Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.6 Kuwait
      • 9.5.6.1 Target Disease Prevalence
      • 9.5.6.2 Competitive Scenario
      • 9.5.6.3 Regulatory Framework
      • 9.5.6.4 Reimbursement Scenario
      • 9.5.6.5 Kuwait Cell & Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10 Competitive Landscape

  • 10.1 Strategy Framework
  • 10.2 Market Participation Categorization
  • 10.3 Company Profiles
    • 10.3.1 Thermo Fisher Scientific, Inc.
      • 10.3.1.1 Company Overview
      • 10.3.1.2 Financial Performance
      • 10.3.1.3 Product Benchmarking
      • 10.3.1.4 Strategic Initiatives
    • 10.3.2 Merck Kgaa
      • 10.3.2.1 Company Overview
      • 10.3.2.1.1 Milliporesigma
      • 10.3.2.2 Financial Performance
      • 10.3.2.3 Product Benchmarking
      • 10.3.2.4 Strategic Initiatives
    • 10.3.3 Lonza
      • 10.3.3.1 Company Overview
      • 10.3.3.2 Financial Performace
      • 10.3.3.3 Product Benchmarking
      • 10.3.3.4 Strategic Initiatives
    • 10.3.4 Catalent, Inc.
      • 10.3.4.1 Company Overview
      • 10.3.4.2 Financial Performance
      • 10.3.4.3 Product Benchmarking
      • 10.3.4.4 Strategic Initiatives
    • 10.3.5 Takara Bio, Inc.
      • 10.3.5.1 Company Overview
      • 10.3.5.2 Financial Performance
      • 10.3.5.3 Product Benchmarking
      • 10.3.5.4 Strategic Initiatives
    • 10.3.6 F. Hoffmann-La Roche Ltd.
      • 10.3.6.1 Company Overview
      • 10.3.6.2 Financial Performance
      • 10.3.6.3 Product Benchmarking
      • 10.3.6.4 Strategic Initiatives
    • 10.3.7 Wuxi Advanced Therapies
      • 10.3.7.1 Company Overview
      • 10.3.7.2 Financial Performance
      • 10.3.7.3 Product Benchmarking
      • 10.3.7.4 Strategic Initiatives
    • 10.3.8 Samsung
      • 10.3.8.1 Company Overview
      • 10.3.8.1.1 Samsung Biologics
      • 10.3.8.2 Company Overview
      • 10.3.8.3 Financial Performance
      • 10.3.8.4 Product Benchmarking
      • 10.3.8.5 Strategic Initiatives
    • 10.3.9 Boehringer Ingelheim International Gmbh
      • 10.3.9.1 Company Overview
      • 10.3.9.2 Financial Performance
      • 10.3.9.3 Product Benchmarking
      • 10.3.9.4 Strategic Initiatives
    • 10.3.10 Novartis Ag
      • 10.3.10.1 Company Overview
      • 10.3.10.2 Financial Performance
      • 10.3.10.3 Product Benchmarking
      • 10.3.10.4 Strategic Initiatives
    • 10.3.11 Hitachi Chemical Co., Ltd. (Showa Denko Materials Co Ltd)
      • 10.3.10.1 Company Overview
      • 10.3.10.1.1 Apceth Biopharma
      • 10.3.10.2 Company Overview
      • 10.3.10.3 Financial Performance
      • 10.3.10.4 Product Benchmarking
      • 10.3.10.5 Strategic Initiatives
    • 10.3.12 Cellular Therapeutics
      • 10.3.12.1 Company Overview
      • 10.3.12.2 Product Benchmarking
    • 10.3.13 Miltenyi Biotech
      • 10.3.13.1 Company Overview
      • 10.3.13.2 Financial Performance
      • 10.3.13.3 Product Benchmarking
      • 10.3.13.4 Strategic Initiatives
    • 10.3.14 Bluebird Bio Inc.
      • 10.3.14.1 Company Overview
      • 10.3.14.2 Financial Performance
      • 10.3.14.3 Product Benchmarking
      • 10.3.14.4 Strategic Initiatives
  • 10.4 Recent Developments And Impact Analysis By Key Market Participants
  • 10.5 Company Mapping
  • 10.6 Vendor Landscape
    • 10.6.1 List Of Key Distributors And Channel Partners
    • 10.6.2 Key Company Market Share Analysis, 2022
  • 10.7 Public Companies
    • 10.7.1 Company Market Position Analysis
    • 10.7.2 Competitive Dashboard Analysis
  • 10.8 Private Companies
    • 10.8.1 List Of Key Emerging Companies
    • 10.8.2 Regional Network Map
    • 10.8.3 Company Market Position Analysis

List of Tables

  • Table 1 List of secondary sources
  • Table 2 CMO Investments in API Biologics - Cell, Gene, Vaccine, and Virus, April - July 2020
  • Table 3 FDA approved Cellular and Gene Therapy Products as of July 2020
  • Table 4 Cell and Gene Therapy Products approved in the European Union
  • Table 5 Summary of risk factors associated with COVID-19 transmission in cell and gene therapy manufacturing
  • Table 6 Impact Analysis
  • Table 7 List of cell therapy manufacturers:
  • Table 8 List of potential end-users
  • Table 9 List of emerging players
  • Table 10 List of market differentiators
  • Table 11 Competitive dashboard analysis
  • Table 12 Regional network map
  • Table 13 Top cell therapy companies of 2022
  • Table 14 Testing methods
  • Table 15 Best Practices for the effective control of raw material
  • Table 16 Operating CMOs/ CDMOs for cell and gene therapy manufacturing in the North America
  • Table 17 Cell and Gene Therapy Manufacturing Capacity in North America as of 2018
  • Table 18 Operating CMOs/ CDMOs for cell and gene therapy manufacturing in the EU
  • Table 19 Cell & Gene Therapy Manufacturing Capacities in Europe 2017
  • Table 20 Distribution of cleanroom footprint, and QC footprint across the U.K.
  • Table 21 Aggregated total number of cellular therapy product manufacturing facilities, GMP laboratories, manufacturing and quality staff, parallel processes and projects by country and state/region.
  • Table 22 Noteworthy regenerative medicine CMOs in operation in Japan
  • Table 23 North America cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 24 North America cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 25 North America cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 26 North America cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 27 North America cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 28 U.S. cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 29 U.S. cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 30 U.S. cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 31 U.S. cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 32 U.S. cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 33 Canada cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 34 Canada cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 35 Canada cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 36 Canada cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 37 Canada cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 38 Europe cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 39 Europe cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 40 Europe cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 41 Europe cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 42 Europe cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 43 Germany cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 44 Germany cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 45 Germany cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 46 Germany cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 47 Germany cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 48 U.K. cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 49 U.K. cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 50 U.K. cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 51 U.K. cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 52 U.K. cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 53 Italy cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 54 Italy cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 55 Italy cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 56 Italy cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 57 Italy cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 58 France cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 59 France cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 60 France cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 61 France cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 62 France cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 63 Spain cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 64 Spain cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 65 Spain cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 66 Spain cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 67 Spain cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 68 Denmark cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 69 Denmark cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 70 Denmark cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 71 Denmark cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 72 Denmark cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 73 Sweden cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 74 Sweden cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 75 Sweden cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 76 Sweden cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 77 Sweden cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 78 Norway cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 79 Norway cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 80 Norway cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 81 Norway cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 82 Norway cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 83 Asia Pacific cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 84 Asia Pacific cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 85 Asia Pacific cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 86 Asia Pacific cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 87 Asia Pacific cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 88 Japan cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 89 Japan cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 90 Japan cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 91 Japan cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 92 Japan cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 93 China cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 94 China cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 95 China cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 96 China cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 97 China cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 98 India cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 99 India cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 100 India cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 101 India cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 102 India cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 103 South Korea cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 104 South Korea cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 105 South Korea cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 106 South Korea cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 107 South Korea cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 108 Thailand cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 109 Thailand cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 110 Thailand cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 111 Thailand cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 112 Thailand cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 113 Australia cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 114 Australia cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 115 Australia cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 116 Australia cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 117 Australia cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 118 Latin America cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 119 Latin America cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 120 Latin America cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 121 Latin America cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 122 Latin America cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 123 Brazil cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 124 Brazil cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 125 Brazil cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 126 Brazil cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 127 Brazil cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 128 Mexico cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 129 Mexico cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 130 Mexico cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 131 Mexico cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 132 Mexico cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 133 Argentina cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 134 Argentina cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 135 Argentina cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 136 Argentina cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 137 Argentina cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 138 MEA cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 139 MEA cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 140 MEA cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 141 MEA cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 142 MEA cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 143 South Africa cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 144 South Africa cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 145 South Africa cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 146 South Africa cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 147 South Africa cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 148 Saudi Arabia cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 149 Saudi Arabia cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 150 Saudi Arabia cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 151. Saudi Arabia cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 152 Saudi Arabia cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 153 UAE cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 154 UAE cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 155 UAE cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 156 UAE cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 157 UAE cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)
  • Table 158 Kuwait cell & gene therapy manufacturing market, by therapy type, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 159 Kuwait cell therapy manufacturing market, by cell type, 2018 - 2030 (USD Million)
  • Table 160 Kuwait cell & gene therapy manufacturing market, by scale, 2018 - 2030 (USD Million)
  • Table 161 Kuwait cell & gene therapy manufacturing market, by mode, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Table 162 Kuwait cell & gene therapy manufacturing market, by workflow, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Medicines in development, by disease
  • Fig. 9 Classification of companies
  • Fig. 10 Cell and gene therapy manufacturing market snapshot, 2022 (USD Million)
  • Fig. 11 Cell & gene therapy manufacturing market segmentation
  • Fig. 12 Market dynamics
  • Fig. 13 Market driver relevance analysis (Current & future impact)
  • Fig. 14 Most common therapeutic areas targeted by cell therapies in development
  • Fig. 15 Gene therapy clinical trials number as of 2021
  • Fig. 16 Regenerative medicine clinical trials
  • Fig. 17 Expedited approval pathway designations by technology
  • Fig. 18 Market restraint relevance analysis (Current & future impact)
  • Fig. 19 Cell and gene therapy market SWOT analysis
  • Fig. 20 Cell and gene therapy market Porter's five forces analysis
  • Fig. 21 Cell therapy manufacturing collaborations from 2014 to 2018
  • Fig. 22 Areas of disruption due to COVID-19 reported by respondents
  • Fig. 23 Global financings for Cell and Gene therapy. (USD Billion)
  • Fig. 24 UK cell and gene therapy manufacturing capacity, 2016 to 2019
  • Fig. 25 Number of gene therapy sites across gene therapy and multifunctional facilities in the UK, 2019
  • Fig. 26 Breakdown of CoGs per process for cell therapy manufacture
  • Fig. 27 Comparison of costs estimated by campaign, day rate, and hybrid models
  • Fig. 28 Campaign model for cell and gene therapies production
  • Fig. 29 Day rate model for cell and gene production
  • Fig. 30 Hybrid model for cell and gene therapies production
  • Fig. 31 The proportion of funds allocation in anti-EBV CTLs and PSCs
  • Fig. 32 Impact Analysis
  • Fig. 33 Cell and gene therapy market: Therapy type outlook and key takeaways
  • Fig. 34 Cell and gene therapy market: therapy type movement analysis
  • Fig. 35 Cell therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 36 Cell therapy manufacturing market estimates and forecast for stem cell therapy, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 37 Cell therapy manufacturing market estimates and forecast for non-stem cell therapy, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 38 Gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 39 Cell and gene therapy manufacturing market: Scale outlook and key takeaways
  • Fig. 40 Cell and gene therapy manufacturing market: Scale movement analysis
  • Fig. 41 Number of cell therapy clinical trials, by phase, 2020
  • Fig. 42 Number of CAR-T cell therapy clinical trials, by phase, as of September 2019
  • Fig. 43 Cell and gene therapy manufacturing market estimates and forecast for precommercial-scale manufacturing, 2018 - 2030 (USD Million)
  • Fig. 44 Cell and gene therapy manufacturing market estimates and forecast for commercial-scale manufacturing, 2018 - 2030 (USD Million)
  • Fig. 45 Cell and gene therapy manufacturing market: Mode outlook and key takeaways
  • Fig. 46 Cell and gene therapy manufacturing market: Mode movement analysis
  • Fig. 47 Cell and gene therapy manufacturing market for contract manufacturing, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 48 Cell and gene therapy manufacturing market for in-house manufacturing, 2018 - 2030 (USD Million) (Volume, Number of Doses)
  • Fig. 49 Cell and gene therapy manufacturing market: Workflow outlook and key takeaways
  • Fig. 50 Cell and gene therapy manufacturing market: Workflow outlook and key takeaways
  • Fig. 51 Cell and gene therapy manufacturing market: Workflow movement analysis
  • Fig. 52 Cell and gene therapy manufacturing market for cell processing, 2018 - 2030 (USD Million)
  • Fig. 53 Cell and gene therapy manufacturing market for cell banking, 2018 - 2030 (USD Million)
  • Fig. 54 Cell and gene therapy manufacturing market for process development, 2018 - 2030 (USD Million)
  • Fig. 55 Cell and gene therapy manufacturing market for fill and finish operations, 2018 - 2030 (USD Million)
  • Fig. 56 Cell and gene therapy manufacturing market for analytical and quality testing, 2018 - 2030 (USD Million)
  • Fig. 57 Cell and gene therapy manufacturing market for raw material testing, 2018 - 2030 (USD Million)
  • Fig. 58 Gene therapy manufacturing facilities: Trends & types
  • Fig. 59 Gene therapy clinical trials
  • Fig. 60 Viral vectors used in clinical trials
  • Fig. 61 Cell and gene therapy manufacturing market for vector production, 2018 - 2030 (USD Million)
  • Fig. 62 Cell and gene therapy manufacturing market for others, 2018 - 2030 (USD Million)
  • Fig. 63 Cell and gene therapy manufacturing market: Regional outlook and key takeaways
  • Fig. 64 Cell and gene therapy manufacturing market: Regional movement analysis
  • Fig. 65 North America cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 U.S. cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Canada cell and gene therapy manufacturing) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Europe cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Germany cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 U.K. cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 France cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Italy cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Spain cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Denmark cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Sweden cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Norway cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Asia Pacific cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Japan cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 China cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 India cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 South Korea cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Australia cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Thailand cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Latin America cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Brazil cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 Mexico cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 87 Argentina cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Middle East & Africa cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 89 South Africa cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Saudi Arabia cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 UAE cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait cell and gene therapy manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 93 Strategy framework
  • Fig. 94 Market participation categorization